Print the page
Increase font size
Groundhog Day (Lockdown Edition)

Groundhog Day (Lockdown Edition)

Chris Campbell

Posted August 23, 2023

Chris Campbell

Alex Jones.

The name alone is enough to spark heated debates in homes and social circles across the nation.

It’s synonymous with conspiracy theories, fiery rhetoric, and a style of journalism that is unashamedly provocative.

When Jones speaks, people either seethe… or cheer… or run away… or tiptoe closer with feigned disinterest.

As usual, Jones has stirred the pot yet again…

Igniting a flurry of speculation on Musk's former bird app, X.

And… what if he’s right?

(Broken clocks. Blind squirrels. And all that.)

The Informant!

In case you missed it: 

According to Jones, a “high-level manager in the TSA,” risking much to break rank and step into the light, has confided in him.

The word from the informant? By the time the leaves turn and October graces us, travelers might find themselves once again ensnared in the tangled weave of face masks.

And…

As winter's icy grip approaches, and December takes hold, there may be a return to the all-too-familiar dance of restrictions and lockdowns.

Normally, we’d shrug it off. Claims of “secret whistleblowers” are a dime-a-dozen online.

But, the thing…

The media is indeed ramping up the rhetoric on lockdowns, booster shots, and masks.

To wit:

CNN Tweet

No less, major Hollywood studio Lionsgate… George Morris Brown College… Rutgers University… and more have already announced fresh new mandates.

What if we are in for another round of lockdowns?

Who stands to benefit? What are the paranoids doing to prepare?

And what’s the one “variant-proof” investment that should do well either way?

The Groundhog Day Portfolio

Let’s take a trip down memory lane.

As lockdowns halted travel, astute investors eyed put options on major oil companies, foreseeing a decline in oil demand.

Meanwhile, the heightened demand for personal protective equipment due to lockdowns increased the allure of stocks from key PPE manufacturers.

The global urgency for vaccination thrust pharmaceutical giants into the limelight, particularly as new COVID-19 variants emerged.

The year also marked a pivotal shift towards remote work and telehealth, with companies like Teladoc Health and Zoom becoming integral to this new normal.

But one investment on the “covid 2.0 watchlist” stands out.

By many accounts, it could be poised to succeed regardless.

It’s natural gas.

Extended winter lockdowns boosted the need for heating, favoring investments in natural gas entities. But a cold snap would do that regardless.

Also, since a lot of natural gas travels through the Panama Canal -- which is, of course, experiencing a drought -- that could also push prices up, too.

Should you believe the hype? That’s up to you.

But the point is to win no matter what.

SpaceX’s Trillion-Dollar Alarm Clock

Posted June 05, 2026

By Chris Campbell

Next week, Altucher Confidential is doing something we've never done before: getting up early.

The Troll, the Champ, and Elon Musk

Posted June 04, 2026

By James Altucher

Even if you don’t care about chess, this story is important for investors to understand.

Apple to $10 Trillion

Posted June 03, 2026

By James Altucher

Your first mistake will be to laugh. Your second mistake will be to buy Apple.

The Gorilla Glass Trade

Posted June 02, 2026

By Chris Campbell

Apple was "late" to music, phones, tablets, watches—and dominated every one. Now they're "late" to AI. Here’s what happens next.

I Made $416,000 on Micron. Here’s What I Bought Today

Posted June 01, 2026

By Chris Campbell

Nobody’s talking about this because they’re all so focused on SpaceX. But the time to get positioned is right now.

The AI Trade Has 10 Days Left

Posted May 29, 2026

By Chris Campbell

After June 8, every analyst on CNBC catches up. The whole game is getting there first.